Screener
Avalo Therapeutics AVTX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Loss before taxes | (36,340) | (20,749) | (55,959) | (33,890) |
| Income tax expense | 18 | 16 | 29 | 24 |
| Net loss | $(36,358) | $(20,765) | $(55,988) | $(33,914) |
| Net loss per share of common stock, basic and diluted | $(0.83) | $(1.92) | $(1.75) | $(3.18) |
| Weighted average common shares outstanding | 43,602,044 | 10,829,760 | 31,919,388 | 10,673,200 |
| Comprehensive loss: | ||||
| Net loss | $(36,358) | $(20,765) | $(55,988) | $(33,914) |
| Other comprehensive loss: |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's EPS (diluted)?
- Avalo Therapeutics (AVTX) reported EPS (diluted) of -$0.83 in Q2 2026.
- How has Avalo Therapeutics's EPS (diluted) changed year-over-year?
- Avalo Therapeutics's EPS (diluted) increased by 56.8% year-over-year, from -$1.92 to -$0.83.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Avalo Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude